Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Xcite, ReNeuron, CPL Resources

Thu, 28th Jan 2010 11:25

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea.ReNeuron group climbed after the stem cell developer said Phase 1 trials for its ReN001 stroke treatment should be given the green light soon following a favourable response to data provided to the UK Gene Therapy Advisory Committee.Irish recruitment group CPL Resources tumbled Thursday as it reported a big drop in gross profit and much lower revenue for the six months to 31 December.Gross profit fell 37% to €13m and profit before tax and an impairment charge of €4.5m in 2008 slumped to €2.4m from €6m. Revenue sank to €91.4m from €118.9m.Publishing Technology, which provides software and services to the publishing industry, says delays to project spend in both the UK and US because of the recession mean revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) will be unchanged from the year before.But earnings before tax are expected to be 'significantly' better as 2009 contains no further amortisation of intangible assets or provisions for onerous leases.Product development software specialist Sopheon predicts revenues for the year ended 31 December 2009 will exceed £8m, although that's down from £9.3m in 2008.Chairman Barry Mence says a profitable fourth quarter shows that 'we reacted appropriately to balancing investment with cost containment'. 'Our current pipeline, coupled with our unique solution set and the continued maturing of our chosen market, gives me continued confidence in our quest to improve shareholder value.'Internet booth and WiFi hotspot provider Spectrum Interactive has completed the roll-out of WiFi services across the motorway service station estate of Moto Hospitality. 'This is an important contract for Spectrum, as it is first to bring Spectrum's WiFi service to the UK motorway services sector.Film finance provider and movie promoter Intandem has made a 'positive start' to 2010. It has completed one film, "The Kid", which it expects to show at the Berlin Flim Festival in February, and has four more films in post-production, all of which should be ready for the Cannes film festival.The s still in advanced negotiations to settle the £5.7m loan and expects to make a further announcement in due course.Asia-focused online advertising sales company Pixel Interactive is to lose a customer that provided a substantial proportion of its turnover in 2009. The company is in negotiations with the customer to minimise the impact on Pixel, but the change is likely to have a material impact on Pixel's revenue and profit forecasts for 2010.Online tech retailer Expansys cut losses sharply in the six months to October to just £162,000 against £1.73m. Revenues for the period were £20.4m (2008: £25.3m), but fell 6% on the six months to 30 April 2009. Pre-tax losses were £24,000 (2008: £1.1m). Chief executive Roger Butterworth has stepped down to pursue other business opportunities.Electronic displays group Densitron returned to profitability in the second half of 2009 and expects to return a small profit for the year as a whole.Advanced Medical Solutions says Cardinal Health, a major US healthcare services company, is marketing and distributing AMS's LiquiBand topical skin adhesive range in the US to hospitals, care centres, and surgeries.Hansard Global reports new business in Q2 2009/10 was 25% ahead of Q1 at £40.9m. The group had $1.16bn of Assets under Administration at 31 December 2009, up 15.6% since 30 June 2009. Policyholder cash flows have been strong through the period;
More News
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more
5 Jul 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

Read more
19 Apr 2018 13:17

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Read more
3 Apr 2018 13:29

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

Read more
26 Mar 2018 15:53

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

Read more
5 Dec 2016 11:06

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Read more
4 Dec 2016 14:45

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

Read more
6 Sep 2016 11:38

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

Read more
7 Jul 2016 09:37

ReNeuron Annual Loss Widens As Product Trials Ramp Up

Read more
4 Jul 2016 15:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Jun 2016 07:58

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

Read more
9 Jun 2016 08:55

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

Read more
8 Jun 2016 08:36

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

Read more
15 Mar 2016 09:52

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.